Valaciclovir

Virios Therapeutics’ Announces Dosing of First Patient in IMC-2 Long-COVID Treatment Trial

Retrieved on: 
Monday, August 15, 2022
Research, Managed Care, General Health, Pharmaceutical, Mental Health, Infectious Diseases, Clinical Trials, Science, COVID-19, Biotechnology, FDA, Health, FDA, Short bowel syndrome, Depression, Valaciclovir, Famciclovir, Simplex, Diagnosis, Sleep, PASC, Pain, Attention, Long COVID, Patient, Celecoxib, Therapy, Fatigue, COVID-19, Company, Center, Center of excellence, Conditional sentence, Myalgia, Safety, FM, Anxiety, Functional somatic syndrome, Fibromyalgia, Nasdaq, Chronic fatigue syndrome, Overalls, BHC, Pharmaceutical industry

The dosing of the first patient in this exploratory trial marks an important milestone for Virios, as we develop new combination antiviral therapies to improve care standards for patients suffering from virally mediated diseases, said Greg Duncan, Chairman and Chief Executive Officer of Virios Therapeutics.

Key Points: 
  • The dosing of the first patient in this exploratory trial marks an important milestone for Virios, as we develop new combination antiviral therapies to improve care standards for patients suffering from virally mediated diseases, said Greg Duncan, Chairman and Chief Executive Officer of Virios Therapeutics.
  • Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, such as fibromyalgia (FM).
  • Evidence of IMC-1s efficacy on a broad spectrum of FM outcome measures was previously demonstrated in a Phase 2a clinical trial.
  • BHC is a non-profit, interdisciplinary Center of Excellence advancing the diagnosis and treatment of chronic fatigue disorders, FM, post-viral syndromes, and related comorbidities.

Virios Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 11, 2022
Public Policy, Government, Biotechnology, Pharmaceutical, General Health, Health, FDA, Healthcare Reform, Clinical Trials, FDA, Short bowel syndrome, Valaciclovir, Famciclovir, Trial of the century, CEO, Simplex, Standard of care, Diagnosis, PASC, Research, Patient, Celecoxib, Therapy, COVID-19, Company, Center, Center of excellence, Conditional sentence, FM, Doctor of Philosophy, Webcast, Functional somatic syndrome, Fibromyalgia, Nasdaq, Investor, MD, Time, Chronic fatigue syndrome, Conference, BHC, Pharmaceutical industry

Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including fibromyalgia , today announced financial results for the second quarter ended June 30, 2022.

Key Points: 
  • Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including fibromyalgia , today announced financial results for the second quarter ended June 30, 2022.
  • Research and development expenses for the second quarter ended June 30, 2022 were $2.4 million, compared to $3.2 million for the second quarter ended June 30, 2021.
  • General and administrative expenses for the second quarter ended June 30, 2022 were $1.3 million, compared to $1.1 million for the second quarter ended June 30, 2021.
  • Virios Therapeutics management will host a webcast and conference call on August 11, 2022, at 8:30 a.m.

Virios Therapeutics, Inc. to Present at Investor Summit Group’s Q3 Virtual Conference

Retrieved on: 
Wednesday, August 10, 2022
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, FDA, Short bowel syndrome, Valaciclovir, Famciclovir, Simplex, Diagnosis, Sleep, PASC, Consumer, Pain, Attention, Complimentary, Celecoxib, Therapy, Fatigue, Company, COVID-19, Center of excellence, Center, Conditional sentence, FM, Real estate, Anxiety, Functional somatic syndrome, Communication services sector reshuffle, Fibromyalgia, Conference, Chronic fatigue syndrome, BHC, Pharmaceutical industry, Finance, Technology, Health care

ET

Key Points: 
  • ET
    The conference is completely complementary to qualified investors.
  • Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, such as fibromyalgia (FM).
  • The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors.
  • The Q3 Investor Summit will take place virtually, featuring 90+ companies and over 500 investors comprising institutional investors, family offices, and high net worth investors.

Global Genital Herpes Treatment Market Outlook Report 2022-2027 Featuring Key Vendors - GlaxoSmithKline, Glenmark Pharmaceuticals, Viatris, Novartis, Teva Pharmaceuticals, & Bausch Health Companies - ResearchAndMarkets.com

Retrieved on: 
Friday, August 5, 2022
Infectious Diseases, Pharmaceutical, Health, People, FDA, LGBT, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Woman, Ageing, Valaciclovir, Pharmacy, Retail, Risk, MSM, Famciclovir, Recurrence, Sex organ, Food, Simplex, Population, NE, Geography, GSK, Incidence, IND, Man, HSV, Patient, HSV-2, Company, Genital herpes, Vaccine, STD, OTC, Infection, Awareness, Immunodeficiency, Sanofi, Herpes labialis, WHO, Technology, Herpes simplex virus, HIV, Factor X, Sex, STI, Vertically transmitted infection, Investigational New Drug, Pharmaceutical industry, Birth control, Aciclovir, Aciclovir, Pritelivir, Moderna

The "Genital Herpes Treatment Market - Global Outlook and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Genital Herpes Treatment Market - Global Outlook and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global genital herpes treatment market is segmented based on drug type, distribution channel, virus type, route of administration, and geography.
  • HSV-2 is the leading virus type segment as HSV-2 is the leading cause of genital herpes.
  • North America is the major revenue contributor to the global genital herpes treatment market, with a share of more than 40%.

Virios Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Thursday, August 11, 2022

Retrieved on: 
Thursday, August 4, 2022
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Functional somatic syndrome, Simplex, Diagnosis, COVID-19, Chronic fatigue syndrome, Attention, Anxiety, Fatigue, Investor, PASC, Company, Sleep, Center, Valaciclovir, Nasdaq, Pain, FDA, BHC, Center of excellence, Short bowel syndrome, Conditional sentence, FM, Celecoxib, Webcast, Therapy, Famciclovir, Fibromyalgia, Pharmaceutical industry

Management will also host a webcast and conference call on August 11, 2022 at 8:30 a.m.

Key Points: 
  • Management will also host a webcast and conference call on August 11, 2022 at 8:30 a.m.
  • ET to discuss the results and provide a corporate update.
  • The live and archived webcast of the call may be accessed on the Virios Therapeutics website under the Investors section: Events and Presentations .
  • Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, such as fibromyalgia (FM).

Candel Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, May 12, 2022
Valaciclovir, Company, Consultant, CADL, Research, Doctor of Philosophy, Public relations, Patient, Insurance, PD-1, Therapy, SVB, Society, Candel, American Society of Clinical Oncology, Foreign, Commonwealth and Development Office, Quarter, PD-L1, Silicon Valley Bank, Brain, ASCO, Standard of care, Large-cell lung carcinoma, Lung, Administration, Nivolumab, RAC, Cancer, Growth, GLOBE, Development, MD, State Administrative Expenses, Pharmaceutical industry, Online gambling, Health insurance, Fellow of the Academy of Medical Sciences

NEEDHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.

Key Points: 
  • NEEDHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.
  • Strengthened cash position with a $20.0 million non-dilutive debt financing with Silicon Valley Bank (SVB) in February 2022.
  • Financial Results for the Quarter Ended March 31, 2022
    Cash Position: Cash and cash equivalents as of March 31, 2022 were $94.3 million compared to $82.6 million as of December 31, 2021.
  • Excluding stock-based compensation expense of $492,000 for the three-month period ended March 31, 2022, total operating expenses for the three-month period ended March 31, 2022, were $8.5 million.

Virios Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 12, 2022
Pharmaceutical, Health, Clinical Trials, Valaciclovir, Pain, Company, FM, BHC, Long COVID, Conditional sentence, Research, Nasdaq, Center of excellence, Webcast, Patient, Simplex, Therapy, Functional somatic syndrome, Bateman–Horn conjecture, Clinical trial, PASC, COVID-19, Investor, Fibromyalgia, FDA, Accounting, Center, Conference, Anxiety, Short bowel syndrome, Attention, Celecoxib, Famciclovir, Chronic fatigue syndrome, Diagnosis, Fatigue, CEO, Sleep, Pharmaceutical industry

Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia , today announced financial results for the first quarter ended March 31, 2022.

Key Points: 
  • Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia , today announced financial results for the first quarter ended March 31, 2022.
  • Research and development expenses for the first quarter of 2022 were $2.8 million, compared to $1.7 million for the first quarter of 2021.
  • General and administrative expenses for the first quarter of 2022 were $1.2 million, compared to $1.4 million for the first quarter of 2021.
  • Virios Therapeutics management will host a webcast and conference call on May 12, 2022, at 8:30 a.m.

Virios Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on Thursday, May 12, 2022

Retrieved on: 
Thursday, May 5, 2022
Health, Infectious Diseases, Clinical Trials, Research, Science, Biotechnology, Chronic fatigue syndrome, COVID-19, Sleep, Valaciclovir, Simplex, Pain, Nasdaq, Fatigue, Company, Fibromyalgia, Short bowel syndrome, Webcast, Attention, FDA, Diagnosis, BHC, Anxiety, Functional somatic syndrome, Conditional sentence, Investor, PASC, Center, Famciclovir, Celecoxib, FM, Center of excellence, Therapy, Pharmaceutical industry

Management will also host a webcast and conference call on May 12, 2022 at 8:30 a.m.

Key Points: 
  • Management will also host a webcast and conference call on May 12, 2022 at 8:30 a.m.
  • ET to discuss the results and provide a corporate update.
  • The live and archived webcast of the call may be accessed on the Virios Therapeutics website under the Investors section: Events and Presentations .
  • Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, such as fibromyalgia (FM).

Virios Therapeutics Completes Enrollment of 425 Patients in Phase 2b “FORTRESS” Clinical Trial for Fibromyalgia

Retrieved on: 
Thursday, April 28, 2022
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, FDA, Clinical Trials, Functional somatic syndrome, DNA, CEO, Famciclovir, Time, Fatigue, Simplex, Fibromyalgia, Patient, Nasdaq, Myalgia, FDA, Chronic fatigue syndrome, Pain, Valaciclovir, Therapy, FM, Anxiety, Short bowel syndrome, COVID-19, Food, Celecoxib, Sleep, Company, Conditional sentence, Diagnosis, US, PASC, Center, Ageing, Depression, Chronic fatigue, Physician, BHC, Pain scale, Trial of the century, Enzyme, American College of Rheumatology, Government budget balance, Attention, Population, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, American College, Center of excellence, Pharmaceutical industry, Vaccine, Medical imaging

Virios lead antiviral development candidate, orally administered IMC-1, is a novel, proprietary, fixed dose, antiviral therapy combining famciclovir and celecoxib.

Key Points: 
  • Virios lead antiviral development candidate, orally administered IMC-1, is a novel, proprietary, fixed dose, antiviral therapy combining famciclovir and celecoxib.
  • The FORTRESS study builds on the statistically significant results from the Companys previously completed Phase 2a FM clinical study.
  • Virios Therapeutics is conducting FORTRESS (Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of HSV-1).
  • Evidence of IMC-1s efficacy on a broad spectrum of FM outcome measures was previously demonstrated in a Phase 2a clinical trial.

Candel Therapeutics to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Wednesday, April 27, 2022
ASCO, Virus, Associate, PD-L1, Patient, Nasdaq, Perelman School of Medicine at the University of Pennsylvania, University of Pennsylvania, Valaciclovir, GLOBE, Therapy, MPH, Private Securities Litigation Reform Act, Immunogenic cell death, NSCLC, Cancer, Technology, Company, American Society of Clinical Oncology, HSV, Form, Society, University, SEC, Lung cancer, Content discovery platform, CADL, Pharmaceutical industry, Vaccine, MD, Candel

NEEDHAM, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that an abstract has been accepted for presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting 2022, which will be held in person from June 3 7, 2022, at the McCormick Place Convention Center in Chicago, Illinois.

Key Points: 
  • NEEDHAM, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that an abstract has been accepted for presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting 2022, which will be held in person from June 3 7, 2022, at the McCormick Place Convention Center in Chicago, Illinois.
  • The presented data will detail clinical outcomes from Candels phase 2 clinical trial evaluating CAN-2409 and valacyclovir in combination with anti-PD-1 or PD-L1 agents in patients with stage III/IV NSCLC.
  • CAN-2409 is the lead product candidatefrom the adenovirus platform and CAN-3110 is the lead product candidate from the HSV platform.
  • The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.